Biogen Inc.
BIIB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $9,676 | $9,836 | $10,173 | $10,982 |
| % Growth | -1.6% | -3.3% | -7.4% | – |
| Cost of Goods Sold | $2,310 | $2,533 | $2,278 | $2,110 |
| Gross Profit | $7,366 | $7,302 | $7,895 | $8,872 |
| % Margin | 76.1% | 74.2% | 77.6% | 80.8% |
| R&D Expenses | $2,489 | $2,703 | $2,597 | $3,401 |
| G&A Expenses | $2,320 | $2,431 | $2,355 | $2,581 |
| SG&A Expenses | $2,387 | $2,502 | $2,409 | $2,680 |
| Sales & Mktg Exp. | $67 | $71 | $54 | $99 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4,875 | $5,205 | $5,006 | $6,081 |
| Operating Income | $2,490 | $2,097 | $2,889 | $2,791 |
| % Margin | 25.7% | 21.3% | 28.4% | 25.4% |
| Other Income/Exp. Net | -$584 | -$801 | $705 | -$1,011 |
| Pre-Tax Income | $1,906 | $1,297 | $3,594 | $1,780 |
| Tax Expense | $274 | $135 | $633 | $53 |
| Net Income | $1,632 | $1,161 | $3,047 | $1,556 |
| % Margin | 16.9% | 11.8% | 29.9% | 14.2% |
| EPS | 11.2 | 8.02 | 20.97 | 10.44 |
| % Growth | 39.7% | -61.8% | 100.9% | – |
| EPS Diluted | 11.19 | 7.97 | 20.87 | 10.4 |
| Weighted Avg Shares Out | 146 | 145 | 145 | 149 |
| Weighted Avg Shares Out Dil | 146 | 146 | 146 | 150 |
| Supplemental Information | – | – | – | – |
| Interest Income | $68 | $277 | $89 | $11 |
| Interest Expense | $250 | $247 | $247 | $254 |
| Depreciation & Amortization | $673 | $495 | $518 | $488 |
| EBITDA | $2,996 | $2,377 | $3,537 | $3,923 |
| % Margin | 31% | 24.2% | 34.8% | 35.7% |